Background: The pathogenesis of thrombocytopenia during the neonatal period in Down's syndrome (DS) infants remains unclear.
Introduction
Diverse hematological abnormalities in newborn infants with Down's syndrome (DS) have been reported. [1] [2] [3] These include neutrophilia, thrombocytopenia, polycythemia, transient myeloproliferative disorder (TMD), neutropenia, thrombocytosis, and anemia. [1] [2] [3] A recent large case series study indicated thrombocytopenia below 150 Â 10 9 per liter in approximately two-third of DS infants during the first week of life, making thrombocytopenia as one of the most common hematological abnormalities. 3 Thrombopoietin (TPO), the ligand for the c-mpl receptor, is the primary regulator of thrombopoiesis and megakaryopoiesis in fetuses and neonates as well as adults. 4 Recently, several studies have clarified the relationship between blood TPO level and platelet count in thrombocytopenic and non-thrombocytopenic non-DS neonates. [5] [6] [7] [8] [9] [10] [11] [12] Accumulating evidence has shown that although neonates of all gestational ages produce endogenous TPO, their TPO response to thrombocytopenia may be suboptimal. 5, 6 In contrast with extensive studies about thrombocytopenia in non-DS neonates, [5] [6] [7] [8] [9] [10] [11] [12] little is known about underlying mechanisms including TPO contribution responsible for thrombocytopenia in DS newborns. There is one report determining TPO levels in DS infants, but this study dealt with only patients complicated by TMD. 13 In addition to TPO, genetic studies have recently provided novel insights into the molecular and transcriptional factors, such as GATA1, FOG-1, and NF-E2, in regulation of megakaryocyte differentiation and thrombopoiesis. 14, 15 Furthermore, somatic mutations in the GATA1 have been shown to be associated with cases of DS-acute megakaryocytic leukemia and TMD. 16, 17 However, because GATA1 mutations are detected in only 3.8% of DS at birth 18 and because neonatal thrombocytopenia spontaneously resolves within a few weeks in most cases, 3 these mutations are unlikely involved in the pathogenesis of transient thrombocytopenia of DS newborns. Therefore, this study is aimed to elucidate the regulatory mechanisms of TPO on thrombocytopenia in DS newborns, irrespective of the presence of TMD complications. To address this issue, we serially determined blood TPO levels and platelet counts in DS infants during the neonatal period.
Methods
Twelve DS infants born at Nishi-Kobe Medical Center between January 1997 and December 2007 participated in this study. DS was diagnosed by clinical characteristics at birth and was confirmed by G-banding karyotyping using peripheral lymphocytes. All subjects had conventional 21 trisomy.
Complete blood count was routinely examined during early infancy, as a substantial proportion of DS infants are known to have hematological abnormalities. [1] [2] [3] Blood samples were principally collected at birth from umbilical cord blood (on day 0) on days 2 and 5 (screening period for inherited metabolic disorders) and, in addition, on periods of follow-up when patients showed complete blood count abnormalities. Blood samples were immediately centrifuged and stored at À30 1C until assay for TPO levels. We obtained approval from the institutional research committee and written informed consent from the children's parents.
TPO levels were measured on 44 serum samples using a double sandwich enzyme-linked immunosorbent assay, which was earlier validated. 19 The lowest detectable limit was 0.40 fmol ml -1 . As normal controls, we used the results of our earlier works, which evaluated the reference interval of serum TPO levels throughout childhood. 20 As significant correlation of TPO values between serum and plasma was shown, 20 we determined blood TPO levels in serum in this study.
Differences between two groups were determined using a twosided Mann-Whitney U-test. Differences in the proportion of two groups were examined with Fisher's exact test. The relationship between TPO level and continuous variables was assessed by Pearson's correlation coefficient. A P value <0.05 was considered as significant. One serum sample obtained from a term DS infant had a TPO concentration less than the detection limit of our assay (0.40 fmol ml -1 ). Therefore, the TPO level of this sample was arbitrarily indicated as 0.20 fmol ml -1 .
Results
Twelve DS infants consisted of seven males and five females. They were born at a mean gestational age of 37.9±1. ) weeks with a mean body weight of 2871±449 (range 2078-3718) g. Median Apgar score at 1 and 5 min was 8 (range 7-10) and 9 (range 8-10), respectively. Six infants were complicated by congenital heart disease. There were no patients with liver dysfunction, defined as >50 IU l -1 of alanine aminotransferase. Maternal complication such as pregnancy-induced hypertension was not observed in any mothers.
Complete blood count was examined in 12 DS infants by a mean sampling number of 5.3 (range 2-13) times during the neonatal period. Thrombocytopenia <150 Â 10 9 per liter, <100 Â 10 9 per liter, and <50 Â 10 9 per liter was observed in seven (58%), four (33%), and one (8%) patients, respectively. In all but one patient with TMD, thrombocytopenia resolved within 15 days. Both TMD and thrombocytopenia of the one remaining patient recovered at 3 months of age. Two patients received platelet transfusion. One infant had massive gastrointestinal bleeding, duodenal stenosis, and TMD on day 0 (platelet count 79 Â 10 9 per liter), and this patient also received red blood cell transfusion. The other patient showed extensive petechiae and lethargy at birth (platelet count 43 Â 10 9 per liter). TPO concentrations in 44 sera from 12 infants are shown in Figure 1 . The timing collected was on day 0 (n ¼ 12), on day 2 (n ¼ 10), on day 5 (n ¼ 12), on days 11-15 (n ¼ 7), and on days 28-30 (n ¼ 3). Our study included two late preterm infants, but as they were just before term, they can be considered as term from a hematological perspective. 20 and found no differences of TPO concentrations between DS and historical non-DS subjects 20 at any sample periods. Figure 2 illustrates the kinetic changes of TPO concentration in 12 DS infants, dividing two subgroups: those without Thrombopoietin and thrombocytopenia in Down's syndrome K Matsubara et al thrombocytopenia (non-thrombocytopenic group, n ¼ 5) and those who had a platelet count <150 Â 10 9 per liter at least once (thrombocytopenic group, n ¼ 7). There was no significant difference in the median TPO levels between two subgroups on day 0 (n ¼ 4 in thrombocytopenic group vs n ¼ 7 in nonthrombocytopenic group), on day 2 (n ¼ 4 in thrombocytopenic group vs n ¼ 6 in non-thrombocytopenic group), or on day 5 (n ¼ 5 in thrombocytopenic group vs n ¼ 7 in nonthrombocytopenic group). On account of the limited number, samples drawn on days 11-15 and days 28-30 were not included in the analysis. In both subgroups, DS infants with low TPO concentrations in the early neonatal period generally showed low values during the subsequent neonatal period (Figure 2) . Contrarily, one thrombocytopenic DS patient who showed an extremely high TPO concentration (18.0 fmol ml -1 ) at birth showed persistently high levels during 2 weeks of age (17.0-35.3 fmol ml -1 ) (Figure 2 ). One preterm DS patient complicated by TMD showed low TPO concentrations of 0.84, 1.38, 0.84, 0.99, and 1.75 fmol ml -1 on days 0, 2, 5, 14, and 28, respectively (Figure 1 ). There was no apparent relationship between these TPO concentrations and each blast count of 2.72, 1.62, 1.45, and 1.13 Â 10 9 per liter. Furthermore, there was no association between TPO level and each platelet count of 79, 193, 87, 75, and 74 Â 10 9 per liter.
We could measure serum TPO concentration and platelet count in 40 samples collected simultaneously. In analysis of these 40 pairs, serum TPO did not correlate with platelet counts. Recently, Bonno et al. 13 reported that in DS patients with TMD, TPO values are inversely correlated to the number of blast cells, which express c-Mpl receptors on their surface, thereby regulating TPO values through uptake and catabolism of ligand-receptor mechanisms. Thus, we suppose that patients with TMD had a pathogenesis of thrombocytopenia that was distinct from those without this complication. When the analysis is limited to 35 samples from 11 patients without TMD, there was a significant inverse correlation between serum TPO level and platelet count (Figure 3 , r ¼ À0.38, P ¼ 0.023).
We also examined the change in TPO kinetics after platelet transfusion in two patients. Unexpectedly, TPO levels increased after platelet transfusion in both patients from 18.0 (day 0) to 33.6 fmol ml -1 (day 2) in one patient and from 0.84 (day 0) to 1.38 fmol ml -1 (day 2) in the other patient.
Discussion
This is the first study concerning serum TPO levels and platelet counts in DS neonates. We showed that thrombocytopenia <150 Â 10 9 per liter accounted for 58%. This figure is comparable to that of a recent large study. 3 The most important results derived from this study are kinetic changes of platelet count and serum TPO levels, and the relationship between these two parameters. We compared our TPO results with reference intervals earlier evaluated in healthy infants. 20 We showed that TPO in DS infants rose from birth to day 2, and thereafter gradually decreased by the end of the neonatal period. This temporal change is concordant with kinetics in term non-DS infants. 20 Considerable evidence suggests that TPO production is constitutive and that circulating TPO levels are regulated by the rate of c-Mpl receptor-mediated degradation after TPO uptake into platelets and megakaryocytes. 4 We found an inverse correlation between serum TPO levels and platelet counts in subjects excluding one TMD patient. These findings support the concept that TPO has an important function in the regulation of platelet production in DS neonates. However, in analysis between thrombocytopenic and non-thrombocytopenic subgroups, median TPO levels were similar between these two groups. This is contrary to the findings by Albert et al., 9 who compared TPO levels in non-DS infants with thrombocytopenia to those without thrombocytopenia. They showed that thrombocytopenic term and preterm infants had median TPO levels approximately 4.6-and 1.9-fold those in nonthrombocytopenic healthy controls, respectively. 9 Murray and coworkers also showed results similar to those of Albert et al. in thrombocytopenic term and preterm non-DS babies. 6, 7 Furthermore, in our analysis, platelet transfusion or recovery from thrombocytopenia did not apparently affect TPO concentrations. Taken together, our finding that thrombocytopenic DS babies dose not have higher TPO levels during the neonatal period raises a possibility that the response of TPO system to thrombocytopenia may be much more suboptimal in DS.
There are several plausible explanations for thrombocytopenia in DS. TPO is produced predominantly in the liver. 4 DS neonates, especially those with TMD, frequently have liver dysfunction. 21, 22 However, as all our subjects showed a normal range of aminotransferase, decreased TPO production was unlikely to explain the suboptimal TPO response to thrombocytopenia. With complicated delivery or neonatal asphyxia, reduced platelet counts have been shown in non-DS neonates. 23, 24 However, none of the infants in our analysis was affected by such perinatal factors. Of more importance, recent genetic studies have shown that there are numerous transcriptional factors in regulation of megakaryocyte differentiation and thrombopoiesis. 14, 15 Of these, there are mutations in the key megakaryocyte transcriptional factor GATA1 in DS neonates with a clinical diagnosis of TMD. 16, 17 However, as we and others 3 have shown that thrombocytopenia in DS is limited to several weeks after birth, this phenomenon is unlikely to be determined by mutations in genetic or transcriptional factors. Kirsammer et al. 25 recently analyzed blood cell development in the Ts65Dn mouse model, which are trisomic for 104 orthologs of Hsa21 genes and are widely used mouse model of DS. They showed that TsDn mouse did not develop thrombocytopenia, but rather myeloproliferative disease, characterized by profound thrombocytosis, megakaryocyte hyperplasia, and dysplastic megakaryocyte morphology. 25 Several studies using human trisomy 21 fetal livers have also shown a cell-autonomous enhanced proliferation of megakaryoblastic cells. 17 Overall, the exact mechanisms responsible for thrombocytopenia during the early neonatal period in DS are unclear according to our TPO analysis or recent evidence from the genetic or molecular studies in DS.
This study has certain limitations. First, the series was small and the results may be preliminary. However, given that the incidence of thrombocytopenia was comparable to that in a recent large study, 3 we consider that there were minimal biases in the thrombocytopenic conditions and TPO concentrations. Second, timing and number of samples drawn from DS patients were not uniform among individuals. Therefore, we may have underestimated the incidence of thrombocytopenia and may not have fully clarified the TPO contribution to thrombocytopenia. Third, our study did not examine c-Mpl expression on platelets or molecular and transcriptional factors involved in megakaryopoiesis. These might coordinate the regulation of TPO concentrations.
In conclusion, we showed, for the first time, that the TPO value and its kinetic change in DS neonates were similar to those in non-DS patients, and that there was an inverse correlation between the serum TPO concentration and platelet count among DS patients without TMD. In most thrombocytopenic DS patients, the TPO concentration was low relative to the degree of thrombocytopenia. However, it must be stressed that these findings need to be confirmed by larger studies.
